Long-term outcome of patients with high-risk prostate cancer following radical prostatectomy and stage-dependent adjuvant androgen deprivation

Urologia Internationalis

Volumn 84, Issue 2, 2010, Pages 164-173

  Spahn, Martin ^a,b   Weiss, Christel ^c   Bader, Pia ^a   Ströbel, Philipp ^c   Gerharz, Elmar W ^b   Kneitz, Burkard ^b   Frohneberg, Detlef ^a  

^a STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Androgen deprivation; High risk prostate cancer; Radical prostatectomy

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; DISEASE SEVERITY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE BIOPSY; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR BIOPSY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANDROGENS; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 77949361843     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000277593     Document Type: Article

References (29)

1. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomas-zewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974.
2. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR: Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). The J Urol 2003; 170:S21-S25; discussion S26-S27.
3. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-106.
4. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997; 15: 1013-1021.
5. Walsh PC: Anatomic radical prostatectomy: evolution of the surgical technique. J Urol 1998; 160: 2418-2424.
6. Sobin L, Wittekind C: TNM Classification of Malignant Tumors, ed 6. New York, Wiley-Liss, 2002.
7. Carroll PR, Lee KL, Fuks ZY, Kantoff PW: Cancer of the prostate; in De Vita V, Hellmann S, Rosenberg SA (ed): Cancer: Principles and Practice of Oncology. Philadelphia, Lippincott Williams & Wilkins, 2001, p 1418.
8. Albertsen PC, Hanley JA, Gleason DF, Barry MJ: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975-980.
9. Zelefsky MJ, Yamada Y, Kollmeier MA, Shippy AM, Nedelka MA: Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer. Eur Urol 2008; 53: 1172-1179.
10. Mian BM, Troncoso P, Okihara K, Bhadkamkar V, Johnston D, Reyes AO, Babaian RJ: Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol 2002; 167: 1675-1680.
11. Manoharan M, Bird VG, Kim SS, Civantos F, Soloway MS: Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of ≥ 8. BJU Int 2003; 92: 539-544.
12. Tewari A, Divine G, Chang P, Shemtov MM, Milowsky M, Nanus D, Menon M: Longterm survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy - a propensity scoring approach. J Urol 2007; 177: 911-915.
13. D'Amico AV, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE, Schultz D, Rhude M, Rocha S, Wein A, Richie JP: Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001; 166: 2185-2188.
14. Yossepowitch O, Eggener SE, Bianco FJ Jr, Carver BS, Serio A, Scardino PT, Eastham JA: Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 2007; 178: 493-499; discussion 499.
15. Tiguert LL, Harrel F, Fradet Y: Disease outcome of patients with a PSA > 20 treated by radical prostatectomy: analysis of 177 patients. J Urol 2006; 175: 311A.
16. Zwergel U, Suttmann H, Schroeder T, Siemer S, Wullich B, Kamradt J, Lehmann J, Stoeckle M: Outcome of prostate cancer patients with initial PSA ≥ 20 ng/ml undergoing radical prostatectomy. Eur Urol 2007; 52: 1058-1066.
17. Hurwitz MD, Schultz D, Richie JP, Wein AJ, Whittington R, Malkowicz SB, D'Amico AV: Radical prostatectomy for high-grade prostate cancer. Urology 2006; 68: 367-370.
18. Akakura K, Isaka S, Akimoto S, Ito H, Okada K, Hachiya T, Yoshida O, Arai Y, Usami M, Kotake T, Tobisu K, Ohashi Y, Sumiyoshi Y, Kakizoe T, Shimazaki J: Long-term results of a randomized trial for the treatment of stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. Urology 1999; 54: 313-318.
19. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC: Long-term biochemical diseasefree and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555-565.
20. Catalona WJ, Smith DS: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152: 1837-1842.
21. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167: 528-534.
22. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152: 1850-1857.
23. Bloom KD, Richie JP, Schultz D, Renshaw A, Saegaert T, D'Amico AV: Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors. Urology 2004; 63: 333-336.
24. Heidenreich A, Varga Z, Von Knobloch R: Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002; 167: 1681-1686.
25. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-479.
26. Steinberg GD, Epstein JI, Piantadosi S, Walsh PC: Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol 1990; 144: 1425-1432.
27. Wyler SF, Engeler DS, Seelentag W, Ries G, Schmid HP: Health-related quality of life after radical prostatectomy and low-dose-rate brachytherapy for localized prostate cancer. Urol Int 2009; 82: 17-23.
28. Gacci M, Lapini A, Serni S, Livi L, Paiar F, Detti B, Simontacchi G, Vittori G, Giubilei G, Mariani M, Palli D, Carini M: Predictors of quality of life after radical treatment for prostate cancer. Urol Int 2008; 80: 231-236.
29. Liatsikos EN, Assimakopoulos K, Stolzenburg JU: Quality of life after radical prostatectomy. Urol Int 2008; 80: 226-230.